GENENTECH, INC.
SOUTH SAN FRANCISCO, CA

Genentech, Inc., a pioneering force in the biotechnology industry for over four decades, is now part of the Roche Group. Established as a leader in discovering, developing, manufacturing, and commercializing innovative medicines for critical medical conditions, Genentech has consistently topped as one of the world's foremost biotech companies. With an extensive portfolio of market products and a promising pipeline, its mission is to provide immediate therapeutic solutions while driving innovation for future needs. Operating under Roche since March 2009, Genentech's South San Francisco campus serves as the hub for Roche’s U.S. pharmaceutical operations. Genentech Research and Early Development continues as an autonomous center within Roche, maintaining its foundational spirit of risk-taking, boundary-pushing experimentation, and a steadfast commitment to ethics, openness, and honesty. Founded in 1976 by Herb Boyer and Bob Swanson over an informal gathering, Genentech has cemented its status as the biotech industry's innovator. Acknowledged as FORTUNE magazine’s "100 Best Companies to Work For" for 20 years consecutively, ranked second on Nature Index's list of Top 100 Corporations based on scientific output from 2012-2016, and earning consistent perfect scores on the Human Rights Campaign Foundation's Corporate Equality Index, Genentech embodies a workplace fostering inclusion, diversity, and respect. The company continues to receive high honors, such as being one of Science Careers’ "Top Twenty Employers" for its 16th consecutive year. Its notable inclusion in Fortune's “100 Best Workplaces for Women” underscores Genentech's dedication to cultivating an inclusive work culture that benefits all employees. Additionally, Working Mother magazine names it among the “100 Best Companies" for working mothers, recognizing flexible work policies. Genentech is headquartered in South San Francisco, California, and maintains operations nationwide with contact points across multiple states. It continues to contribute significantly to corporate philanthropy as evidenced by its ranking on the San Francisco Business Times' list of top Bay Area Corporate Philanthropists. Established in Delaware but closely associated with Southern California through physical presence and community involvement, Genentech is a testament to the power of visionary leadership and unwavering commitment to fostering health benefits globally. Its influential footprint extends far beyond its innovative pharmaceuticals into realms promoting workplace excellence and societal contributions.

KEY FACTS ABOUT GENENTECH, INC.

Company name
GENENTECH, INC.
Status
Active
Filed Number
P25895
FEI Number
942347624
Date of Incorporation
September 5, 1989
Age - 36 years
Home State
DE
Company Type
Foreign for Profit

CONTACTS

Website
http://genentech.com
Phones
(888) 835-2555
(650) 225-4630
(800) 334-0290
(800) 821-8590
(888) 662-6728
(844) 287-3783
(650) 225-1000
(800) 626-3553
(650) 225-6000
(503) 992-3600
(760) 231-2440
(707) 454-1000
(502) 995-4600
(866) 411-4266
(650) 225-2580
(650) 225-2500
(800) 551-2231
(877) 436-3683
(866) 422-2377
(800) 530-3083
(650) 467-6800
(650) 225-5566
(650) 225-8326

GENENTECH, INC. NEAR ME

Principal Address
1 DNA Way,
South San Francisco,
CA,
94080,
US
Mailing Address
Attn: Corporate Legal Department,
1 DNA Way,
South San Francisco,
CA,
94080,
US

See Also

Officers and Directors

The GENENTECH, INC. managed by the three persons from South San Francisco on following positions: Director, Asst, CEO,

Akiko Iwasaki

Position
Director Active
From
South San Francisco, CA, CA

Anjna Mehta

Position
Asst Active
From
South San Francisco, CA, CA

Ashley Magargee

Position
CEO, Active
From
South San Francisco, CA, CA





Registered Agent is CORPORATION SERVICE COMPANY

Address
1201 HAYES STREET, TALLAHASSEE, FL, 32301, 2525

Events

November 6, 2009
CANCEL ADM DISS/REV
September 25, 2009
REVOKED FOR ANNUAL REPORT
April 2, 1996
REINSTATEMENT
August 25, 1995
REVOKED FOR ANNUAL REPORT
November 16, 1993
REINSTATEMENT
August 13, 1993
REVOKED FOR ANNUAL REPORT

Annual Reports

2025
January 21, 2025
2024
March 7, 2024